½ÃÀ庸°í¼­
»óǰÄÚµå
1471955

Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, ¼¼°è ¹× Áö¿ªº° Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® ¸®Æ÷Æ® : Á¦Ç°º°, ¸ð´Þ¸®Æ¼º°, ÃÖÁ¾»ç¿ëÀÚº°

Continuous Renal Replacement Therapy Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Modality, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 1-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

The Insight PartnersÀÇ ÃֽŠÁ¶»ç 'Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀå ¿¹Ãø(-2030³â) : ¼¼°è ºÐ¼® - Á¦Ç°, ¸ð´Þ¸®Æ¼, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª'¿¡ µû¸£¸é 2022³â ½ÃÀå ±Ô¸ð´Â 14¾ï 2,000¸¸ ´Þ·¯·Î, 2030³â¿¡´Â 27¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖÀ¸¸ç, 2022-2030³âÀÇ CAGRÀº 8.7%·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù.

Áö¼ÓÀû ½Å´ëü¿ä¹ý(CRRT)Àº AKI Ä¡·á¸¦ À§ÇØ ÁßȯÀڽǿ¡ ÀÔ¿øÇÑ ¼Ò¾Æ¿¡°Ô ±ÇÀåµÇ´Â Åõ¼® ¿É¼ÇÀ¸·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ¼Ò¾Æ ÁúȯÀÇ ´Ù¾ç¼ºÀ¸·Î ÀÎÇØ ¼Ò¾Æ ȯÀÚ±ºÀÇ ½ÅÀå ´ëü ¿ä¹ýÀÇ ÀûÀÀÁõÀº º¯È­Çϰí ÀÖÀ¸¸ç, CRRTÀÇ Àû¿ë ¹üÀ§´Â ÁÖ·Î ÁßÁõ ½Å»ý¾Æ µî ºñ½ÅÀå Áúȯ¿¡ ´ëÇÑ ÀÔÁõµÈ È¿°ú·Î ÀÎÇØ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¸ÞµåÆ®·Î´ÐÀÇ Ä®Æäµð¿¥ ½Ã½ºÅÛÀº ÀúüÁß È¯ÀÚ¿ë ü¿Ü CRRT·Î, °¡Àå Ãë¾àÇÑ È¯ÀÚµéÀÇ ¿ä±¸¿¡ È¿°úÀûÀ¸·Î ´ëÀÀÇÒ ¼ö ÀÖ´Ù´Â °ÍÀÌ ¸ÞµåÆ®·Î´ÐÀÇ ÁÖÀåÀÔ´Ï´Ù. ¶ÇÇÑ ¹Ú½ºÅÍÀÇ PRISMASOL°ú PHOXILLUM ¼Ö·ç¼ÇÀº ¼Ò¾Æ ¹× ¼ºÀΠȯÀÚÀÇ ÀüÇØÁú°ú »ê¿°±â ºÒ±ÕÇüÀ» ±³Á¤ÇÒ »Ó¸¸ ¾Æ´Ï¶ó Çѿܿ©°ú¸¦ ÅëÇØ Á¦°ÅµÈ Ç÷Àå·®À» º¸ÃæÇÏ´Â CRRTÀÇ ´ëü ¼Ö·ç¼ÇÀ¸·Î ÀûÀÀÁõÀ» °®°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼Ò¾Æ CRRT Àåºñ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Á¦Ç°º° Áö¼ÓÇü ½Å´ëü¿ä¹ý ½ÃÀå ÀλçÀÌÆ®

Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀåÀº Á¦Ç°º°·Î Åõ¼®¾× ¹× º¸Ãæ¾×, ÀÏȸ¿ë, Ç÷¾× ¶óÀÎ ¼¼Æ® ¹× Æ©ºê, CRRT ½Ã½ºÅÛ, Ç÷¾× ÇÊÅÍ·Î ±¸ºÐµÇ¸ç, CRRT ½Ã½ºÅÛ ºÎ¹®ÀÌ 2022³â ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ç÷¾× ÇÊÅÍ ºÐ¾ß´Â 2022-2030³â µ¿¾È ½ÃÀå¿¡¼­ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. Ç÷¾× ÇÊÅÍ´Â Áß°ø »ç¸·À¸·Î ±¸¼ºµÇ¾î ¹èÃâµÇ´Â ¾×ü ¹× ¿ëÁúÀÇ ¾çÀ» Á¦¾îÇÕ´Ï´Ù. ¿ëÁú(³ëÆó¹°, ÀüÇØÁú ¹× ±âŸ ºÐÀÚ)À» Á¦°ÅÇÔÀ¸·Î½á CRRT Ç÷¾× ÇÊÅÍ ¸âºê·¹ÀÎÀº ½ÅÀåÀÇ È°µ¿ÀÇ ÀϺθ¦ ¸ð¹æÇÕ´Ï´Ù. ¶ÇÇÑ ±× ±â´ÉÀº ü¾× »óÅÂ¿Í »ê¿°±â ÆòÇüÀ» ȸº¹ÇÏ´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº° Áö¼ÓÇü ½ÅÀå´ëü¿ä¹ý ½ÃÀå ÀλçÀÌÆ®

Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀåÀº ÃÖÁ¾»ç¿ëÀÚº°·Î º´¿ø, ¿Ü·¡ ȯÀÚ Ä¡·á ¼¾ÅÍ, ÀçÅà ġ·á ¹× ±âŸ·Î ºÐ·ùµÇ¸ç, º´¿ø ºÎ¹®Àº 2022³â Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀçÅà ¸ð´ÏÅ͸µ ºÎ¹®Àº 2022-2030³â °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹ º´¿øÇùȸ¿¡ µû¸£¸é 2023³â ¹Ì±¹¿¡´Â 5,157°³ÀÇ Áö¿ª º´¿ø, 206°³ÀÇ ¿¬¹æ º´¿ø, 107°³ÀÇ ±âŸ º´¿øÀÌ ÀÖ¾ú½À´Ï´Ù. ¶ÇÇÑ ³ëÀÎ Àα¸ Áõ°¡¿Í AKI·Î ÀÎÇÑ ÀÔ¿øÀÇ ÇöÀúÇÑ Áõ°¡´Â º´¿øÀÇ CRRT ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

±¹¸³º¸°Ç¿ø, ±â¾÷ÀÇ ÅõÀÚÀÚ º¸°í¼­, ¼¼°èº¸°Ç±â±¸(WHO) µîÀº Áö¼ÓÇü ½ÅÀå´ëü¿ä¹ý ½ÃÀå¿¡ ´ëÇÑ º¸°í¼­¸¦ ÀÛ¼ºÇÒ ¶§ Âü°íÇÑ ÁÖ¿ä 2Â÷ ÀÚ·á Áß ÀϺÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀå ±¸µµ

  • PEST ºÐ¼®
  • ¿¡ÄڽýºÅÛ ºÐ¼®
    • ¹ë·ùüÀÎÀÇ º¥´õ ¸®½ºÆ®

Á¦5Àå Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ÁÖ¿ä ½ÃÀå ÃËÁø¿äÀÎ
  • ÁÖ¿ä ½ÃÀå ¾ïÁ¦¿äÀÎ
  • ÁÖ¿ä ½ÃÀå ±âȸ
  • ÇâÈÄ µ¿Çâ
  • ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇ⠺м®

Á¦6Àå Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀå - ¼¼°è ½ÃÀå ºÐ¼®

  • Áö¼ÓÀû½Å´ëü¿ä¹ý - ¼¼°è ½ÃÀå °³¿ä
  • Áö¼ÓÀû½Å´ëü¿ä¹ý - ¼¼°è ½ÃÀå ¹× ¿¹Ãø(-2030³â)

Á¦7Àå Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀå - ¸ÅÃ⠺м® - Á¦Ç°º°, 2020-2030³â

  • Åõ¼®¾× ¹× ±³È¯¾×
  • ÀÏȸ¿ë
  • Ç÷¾× ¶óÀÎ ¼¼Æ®¿Í Æ©ºê
  • Ç÷¾× ÇÊÅÍ
  • CRRT ½Ã½ºÅÛ

Á¦8Àå Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀå - ¸ÅÃ⠺м® - ¸ð´Þ¸®Æ¼º°, 2020-2030³â

  • Áö¼ÓÀû Á¤¸ÆÇ÷¾×¿©°ú(CVVH)
  • Áö¼ÓÀû Á¤¸ÆÇ÷¾×¿©°ú(CVVHDF)
  • Áö¼ÓÀû Á¤¸ÆÇ÷¾×Åõ¼®(CVVHD)
  • Â÷ºÐ½Ä Áö¼Ó Çѿܿ©°ú(SCUF)

Á¦9Àå Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀå - ¸ÅÃ⠺м® - ÃÖÁ¾»ç¿ëÀÚº°, 2020-2030³â

  • º´¿ø
  • ¿Ü·¡ ÀÇ·á
  • ÀçÅÃÀÇ·á
  • ±âŸ

Á¦10Àå Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀå - ¸ÅÃ⠺м® - Áö¿ª ºÐ¼®, 2020-2030³â

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ¿µ±¹
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ µ¿³²¾Æ½Ã¾Æ ±¹°¡
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • Áß³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ Áß³²¹Ì

Á¦11Àå ¾÷°è »óȲ

  • ÇÕº´°ú Àμö
  • °è¾à, Á¦ÈÞ, ÇÕº´»ç¾÷
  • ½ÅÁ¦Ç° Ãâ½Ã
  • »ç¾÷ È®´ë¿Í ±âŸ Àü·«Àû °³¹ß

Á¦12Àå °æÀï ±¸µµ

  • ÁÖ¿ä ±â¾÷¿¡ ÀÇÇÑ È÷Æ®¸Ê ºÐ¼®
  • ±â¾÷ÀÇ Æ÷Áö¼Å´×°ú ÁýÁßµµ

Á¦13Àå Áö¼ÓÀû½Å´ëü¿ä¹ý ½ÃÀå - ÁÖ¿ä ±â¾÷ °³¿ä

  • Baxter International Inc
  • Asahi Kasei
  • Fresenius Medical Care
  • Medica S.p.A.
  • Medtronic Plc
  • B. Braun
  • Nikkiso Co Ltd
  • Toray Medical Co Ltd
  • Infomed SA
  • Quanta Dialysis Technologies Inc

Á¦14Àå ºÎ·Ï

KSA 24.05.22

According to our latest study on " Continuous Renal Replacement Therapy Market Forecast to 2030 - Global Analysis -Product, Modality, End User, and Geography," the market was valued at US$ 1.42 billion in 2022 and is expected to reach US$ 2.75 billion by 2030; it is estimated to register a CAGR of 8.7% from 2022 to 2030.

Continuous renal replacement therapy (CRRT) has become the recommended dialysis option for children admitted to ICUs for AKI treatments. The indications for renal replacement in the pediatric population have changed due to a wide range of pediatric diseases. The range of CRRT applications has expanded with its proven effectiveness in treating nonrenal indications, primarily, in critically ill newborns. For instance, the Carpediem system by Medtronic offers a dedicated extracorporeal CRRT for low-weight patients; as per the company's claims, the device responds effectively to the needs of the most fragile patients. Moreover, PRISMASOL and PHOXILLUM solutions by Baxter are indicated as a replacement solution in CRRT to replace plasma volume removed by ultrafiltration as well as to correct electrolyte and acid-base imbalances in pediatric and adult patients. Thus, the increased demand for pediatric CRRT devices benefits the continuous renal replacement therapy market growth.

By Product, Continuous Renal Replacement Therapy Market-Based Insights

Based on product, the continuous renal replacement therapy market is segmented into dialysates and replacement fluids, disposables, bloodline sets and tubes, CRRT systems, and hemofilters. The CRRT systems segment held the largest share of the market in 2022. The hemofilters segment is likely to register the highest CAGR in the market during 2022-2030. The hemofilters are composed of a hollow-fiber membrane that controls the volume of fluids and solutes evacuated. By eliminating solutes (waste products, electrolytes, and other molecules), CRRT hemofilter membranes imitate some of the activities of the kidney. Moreover, they may help restore fluid status and acid-base balance through their function.

By End User, Continuous Renal Replacement Therapy Market-Based Insights

The continuous renal replacement therapy market, by end-user, is segmented into hospitals, ambulatory care centers, home care, and others. In 2022, the hospital segment dominated the continuous renal replacement therapy market share. The home monitoring segment is expected to register the highest CAGR during 2022-2030. In 2023, the US had 5,157 community hospitals, 206 federal government hospitals, and 107 other hospitals, according to the American Hospital Association. Further, the growing elderly population and the notable rise in hospital admissions for AKI are the key factors that propel the demand for CRRT systems in hospitals.

National Institutes of Health, company's investor reports, and the World Health Organization, are a few of the major secondary sources referred to while preparing the report on the continuous renal replacement therapy market.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Continuous Renal Replacement Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Continuous Renal Replacement Therapy Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Continuous Renal Replacement Therapy Market - Global Market Analysis

  • 6.1 Continuous Renal Replacement Therapy - Global Market Overview
  • 6.2 Continuous Renal Replacement Therapy - Global Market and Forecast to 2030

7. Continuous Renal Replacement Therapy Market - Revenue Analysis (USD Million) - By Product, 2020-2030

  • 7.1 Overview
  • 7.2 Dialysates and Replacement Fluids
  • 7.3 Disposables
  • 7.4 Bloodline Sets and Tubes
  • 7.5 Hemofilters
  • 7.6 CRRT Systems

8. Continuous Renal Replacement Therapy Market - Revenue Analysis (USD Million) - By Modality, 2020-2030

  • 8.1 Overview
  • 8.2 Continuous venovenous hemofiltration (CVVH)
  • 8.3 Continuous venovenous hemodiafiltration (CVVHDF)
  • 8.4 Continuous venovenous hemodialysis (CVVHD)
  • 8.5 Slow continuous ultrafiltration (SCUF)

9. Continuous Renal Replacement Therapy Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 9.1 Overview
  • 9.2 Hospital
  • 9.3 Ambulatory care
  • 9.4 Homecare
  • 9.5 Others

10. Continuous Renal Replacement Therapy Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Continuous Renal Replacement Therapy Market Overview
    • 10.1.2 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts to 2030
    • 10.1.3 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts and Analysis - By Product
    • 10.1.4 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts and Analysis - By Modality
    • 10.1.5 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts and Analysis - By End User
    • 10.1.6 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Continuous Renal Replacement Therapy Market
        • 10.1.6.1.1 United States Continuous Renal Replacement Therapy Market, by Product
        • 10.1.6.1.2 United States Continuous Renal Replacement Therapy Market, by Modality
        • 10.1.6.1.3 United States Continuous Renal Replacement Therapy Market, by End User
      • 10.1.6.2 Canada Continuous Renal Replacement Therapy Market
        • 10.1.6.2.1 Canada Continuous Renal Replacement Therapy Market, by Product
        • 10.1.6.2.2 Canada Continuous Renal Replacement Therapy Market, by Modality
        • 10.1.6.2.3 Canada Continuous Renal Replacement Therapy Market, by End User
      • 10.1.6.3 Mexico Continuous Renal Replacement Therapy Market
        • 10.1.6.3.1 Mexico Continuous Renal Replacement Therapy Market, by Product
        • 10.1.6.3.2 Mexico Continuous Renal Replacement Therapy Market, by Modality
        • 10.1.6.3.3 Mexico Continuous Renal Replacement Therapy Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of SouthEast Asia
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 U.A.E
    • 10.4.3 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Continuous Renal Replacement Therapy Market - Key Company Profiles

  • 13.1 Baxter International Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 13.2 Asahi Kasei
  • 13.3 Fresenius Medical Care
  • 13.4 Medica S.p.A.
  • 13.5 Medtronic Plc
  • 13.6 B. Braun
  • 13.7 Nikkiso Co Ltd
  • 13.8 Toray Medical Co Ltd
  • 13.9 Infomed SA
  • 13.10 Quanta Dialysis Technologies Inc

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦